1. Bakker E, Plueschke K, Jonker CJ, Kurz X, Starokozhko V, Mol PGM. Contribution of real-world evidence in EMA regulatory decision making. Clin Pharmacol Ther. 2022 Oct 17.
  1. Christopher Corton J, Mitchell CA, Auerbach S, Bushel JP, Ellinger-Ziegelbauer H, Escobar PA, Froetschl R, Harrill AH, Johnson K, Klaunig JE, Pandiri AR, Podtelezhnikov AA, Rager JE, Tanis KQ, van der Laan JW, Vespa A, Yauk CL, Pettit SD, Sistare FD. A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies. Toxicol Sci. 2022 Apr 11.
  1. Duijndam B, Tedeschi M, van der Stel W, van den Hoorn T, van der Burg B, Bouwman P, van der Laan JW, van de Water B. Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Mar 18.
  1. Hermans AMM, Maliepaard M, Boon WPC, Pasmooij AMG. Impact of the new European Union In Vitro Diagnostics Regulation on the practice of hospital diagnostic laboratories. Expert Rev Mol Diagn. 2022 Jun 14.
  1. van Hunsel FPAM, van der Kooi D, van de Koppel S, Kroes BH, Woerdenbag HJ. Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre Lareb. Drug Saf. 2022 Jun.
  1. Ghalandari N, Crijns HJMJ, Bergman JEH, Dolhain RJEM, van Puijenbroek EP, Hazes JMW. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance. Br J Clin Pharmacol. 2022 Jul 27.
  1. Ismail RK, van Breeschoten J, van der Flier S, van Loosen C, Pasmooij AMG, van Dartel M, van den Eertwegh A, de Boer A, Wouters M, Hilarius D. Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis. J Med Internet Res. 2022 Jun 23.
  1. Ismail RK, Suijkerbuijk KPM, de Boer A, van Dartel M, Hilarius DL, Pasmooij AMG, van Zeijl MCT, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest H, van den Eertwegh AJ, Wouters MWJM. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Res. 2022 Jun 6.
  1. de Jong AJ, Grupstra RJ, Santa-Ana-Tellez Y, Zuidgeest MGP, de Boer A, Gardarsdottir H; Trials@Home consortium. Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019-2020? A cross-sectional study in ClinicalTrials.gov. BMJ Open. 2022 Aug 29.
  1. de Jong AJ, van Rijssel TI, Zuidgeest MGP, van Thiel GJMW, Askin S, Fons-Martínez J, De Smedt T, de Boer A, Santa-Ana-Tellez Y, Gardarsdottir H; Trials@Home Consortium. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective. Clin Pharmacol Ther. 2022 Apr 30.
  1. Jonker CJ, Bakker E, Kurz X, Plueschke K. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol. 2022 Aug 4.
  1. Kemper E, Ghalandari N, Wintjes H, Van Steensel-Boon A, Kranenburg L, Mulders A, Crijns H, Smeele H, Dolhain RJE. Active counselling and well-controlled disease result in a higher percentage of women with rheumatoid arthritis that breast feed: results from the PreCARA study. RMD Open. 2022 Jun.
  1. van der Laan JW, Revision of ICH S8 Needed?. Frontiers in Toxicology, 2022 Apr 25.
  1. Machiels JD, Vries MJA, Kwa MSG, Voskamp L, van Puijenbroek EP, Kramers C. Bijwerkingen van geneesmiddelen Causaliteitsbeoordeling en registratie. Ned Tijdschr Geneesk. 2022;166:D6199.
  1. Maliepaard M, Nibi P, Nibi G, Pasmooij AMG. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency. Front Med (Lausanne). 2022 May 6.
  1. Mantila KM, Pasmooij AMG, Hallgreen CE, Mol PGM, van Boven JF. Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines in the European Union 2010-2020. Clin Pharmacol Ther. 2022 Jul 11.
  1. Michaleas S, Moreno Oliver A, Mueller-Berghaus J, Sarac SB, van der Elst ME, Müller-Egert S, Zander H, Enzmann H, Pignatti F. The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer. ESMO Open. 2022 May 25.
  1. Mitroiu M, Teerenstra S, Oude Rengerink K, Pétavy F, Roes KCB. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework. Pharm Stat. 2022 Jun 9.
  1. Plueschke K, Jonker C, Strassmann V, Kurz X. Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database. Drug Saf. 2022 Jun 21.
  1. Sepodes B, Mol PGM. Editorial: Insights in Regulatory Science 2021. Front Med (Lausanne). 2022 Sep 20.
  1. Vandebriel RJ, Stalpers CAL, Vermeulen JP, Remkes M, Schmelter M, Broere F, Hoefnagel MHN. Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation. Vaccine. 2022 Aug 20.
  1. de Vries E, Bakker E, Monster TBM, Denig P, Mol PGM. Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands. Drug Saf. 2022 Sep 15.
     
  2. de Vries ST, Starokozhko V, Schellens IMM, Wijnans L, Enzmann H, Cavaleri M, Mol PGM. Attention for sex in COVID-19 trials: a review of regulatory dossiers. BMJ Glob Health. 2022 Mar.